Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514735 · ClinicalTrials.gov registry record · Phase 3
Tailored Treatment of Permanent Atrial Fibrillation
A Phase 3 study, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
NCT00514735 is a Phase 3 study that has completed, run by Medtronic Cardiac Rhythm and Heart Failure. The registered enrollment target is 210 participants.
The verdict
NCT00514735, a Phase 3 study, has completed, sponsored by Medtronic Cardiac Rhythm and Heart Failure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
Study Summary
The purpose of this trial is to evaluate the safety and efficacy of the Medtronic Cardiac Ablation System compared to medical therapy in the persistent and long-standing persistent atrial fibrillation population.
Interventions
- PROCEDURE Medtronic Cardiac Ablation System
- DRUG Class I or III Antiarrhythmic Medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514735
The ClinicalTrials.gov registry entry for NCT00514735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Rhythm and Heart Failure, which has 115 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Medtronic Cardiac Ablation System is the first listed.
NCT00514735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00514735 about?
NCT00514735 is a clinical study titled "Tailored Treatment of Permanent Atrial Fibrillation". The purpose of this trial is to evaluate the safety and efficacy of the Medtronic Cardiac Ablation System compared to medical therapy in the persistent and long-standing persistent atrial fibrillation population.
What is the current status of trial NCT00514735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2007-05. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00514735?
The interventions under investigation include: Medtronic Cardiac Ablation System (PROCEDURE), Class I or III Antiarrhythmic Medications (DRUG).
Who is sponsoring clinical trial NCT00514735?
This trial is sponsored by Medtronic Cardiac Rhythm and Heart Failure, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.